Cetera Investment Advisers
HRTX icon

Cetera Investment Advisers’s Heron Therapeutics HRTX Stock Holding History

Cetera Investment Advisers’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.62K Buy
17,861
+3,870
+28% +$3.1K ﹤0.01% 4903
2026
Q1 		$11.2K Sell
13,991
-6
-0% -$7 ﹤0.01% 4689
2025
Q4 		$18.2K Hold
13,997
– – ﹤0.01% 4581
2025
Q3 		$17.6K Buy
13,997
+226
+2% +$358 ﹤0.01% 4497
2025
Q2 		$28.5K Buy
13,771
+1,520
+12% +$3.1K ﹤0.01% 4006
2025
Q1 		$27K Buy
12,251
+1,884
+18% +$3.66K ﹤0.01% 3899
2024
Q4 		$15.9K Sell
10,367
-4,889
-32% -$7.92K ﹤0.01% 3712
2024
Q3 		$30.4K Buy
15,256
+147
+1% +$351 ﹤0.01% 3631
2024
Q2 		$52.9K Buy
15,109
+1,602
+12% +$4.92K ﹤0.01% 3591
2024
Q1 		$37.4K Buy
+13,507
New +$34K ﹤0.01% 3593

Other funds holding HRTX

RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
CC
Clearline Capital New York $1.68B AUM 53.07% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TC
Tejara Capital London, United Kingdom $243M AUM 9.84% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
JAM
JW Asset Management Miami Beach, Florida $320M AUM 140.1% 1-Year Est. Return

Cetera Investment Advisers's HRTX Position: Q2 2026 in Review

Cetera Investment Advisers increased its Heron Therapeutics (HRTX) stake by 28% in Q2 2026, buying an estimated $3.1K and bringing the position to 17,861 shares worth $7.62K. The position accounts for ﹤0.01% of the portfolio, ranked #4903.

Cetera Investment Advisers first reported a position in HRTX in Q1 2024 and has held it in 10 quarters since. The position peaked at $52.9K in Q2 2024. 163 funds tracked by Wall St. Rank hold HRTX as of Q2 2026.

  • Cetera Investment Advisers held 17,861 shares of Heron Therapeutics worth $7.62K as of Q2 2026.
  • Cetera Investment Advisers bought 3,870 Heron Therapeutics shares in Q2 2026, an estimated $3.1K.
  • Heron Therapeutics made up ﹤0.01% of Cetera Investment Advisers's portfolio in Q2 2026, its #4903 holding.
  • Cetera Investment Advisers first reported a position in Heron Therapeutics in Q1 2024 and has held it in 10 quarters since.
  • Cetera Investment Advisers's Heron Therapeutics position peaked at $52.9K in Q2 2024.
  • 163 funds tracked by Wall St. Rank held Heron Therapeutics as of Q2 2026.

Based on Cetera Investment Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.